NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset
NRx Pharmaceuticals shares fell 4.3% to $2.13 in premarket trading after the FDA granted Fast Track status to its ketamine-based NRX-100 for suicidal ideation. The company plans to submit data from over 70,000 U.S. patients to support accelerated approval. Investors await further FDA feedback and updates during the San Francisco healthcare conference.